drugset / Trial / NCT07348861
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
Phase 2
Not yet recruiting
25 enrolled
Zheng Min
Qilu Pharmaceutical Co., Ltd. · collabSichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with iparomlimab and tuvonralimab as neoadjuvant therapy in patients with locally advanced cervical cancer
Timeline
- Start
- 2026-02-01
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 5 mg/kg | Intravenous |
| Subject | Tuvonralimab | Monoclonal antibody | 3 mg/kg | Intravenous |